Compare Globus Medical Inc. Class A Common Stock (GMED) vs Garmin Ltd. (GRMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Garmin Ltd. — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Garmin Ltd. trades at $282.76 (market cap $53.94B). The key difference: Garmin Ltd. is far larger — about 5.3× Globus Medical Inc. Class A Common Stock's market cap, and Garmin Ltd. pays a 1.5% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Garmin Ltd. for 84 Days on average.
| GMED | GRMN | |
|---|---|---|
Market Cap | $10.25B | $53.94B |
Volume | 1,059,528 | 947,987 |
Sector | Health | Technology |
52-Week High | $96.82 | $313.16 |
52-Week Low | $58.33 | $187.10 |
Typical Hold Time | 0 Days | 84 Days |
Enterprise Value | $9.76B | $51.46B |
Dividend Yield | — | 1.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Garmin (GRMN) trades at $276.41, up 3.62% on the day, with a bearish technical signal but strong fundamental performance. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue and net income have shown steady growth, reaching $7.25B and $1.66B respectively in 2025, supported by robust profitability margins. Recent news highlights product innovation and industry recognition.
The outlook is supported by solid earnings growth and a consensus price target of $323.20, implying potential upside. However, risks include competitive pressures in consumer electronics and reliance on discretionary spending. Analyst sentiment is mixed, with a majority hold rating, suggesting cautious optimism amid valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →
